GDTC supply chain intelligence for CytoMed Therapeutics Limited: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
CytoMed Therapeutics Limited (GDTC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| THIRD-PARTY-SERVICE-PROVIDERS | THIRD-PARTY-SERVICE-PROVIDERS | 90% | Some of this information is also processed and stored by our third-party service providers to whom we outsource certain functions |
| ACET | Adicet Bio, Inc. | 72% | Reciprocal relationship from ACET graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidan… |
| ACET | Adicet Bio, Inc. | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidan… |
| ALLO | Allogene Therapeutics, Inc. | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ARTV g… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidan… |
| FATE | Fate Therapeutics, Inc. | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-cl… |
| GILD | Gilead Sciences, Inc. | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| IMTX | Immatics N.V. | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| IMTX | Immatics N.V. | 72% | Reciprocal relationship from IMTX graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidan… |
| IPSC | Century Therapeutics, Inc. | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidan… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guida… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or the introduct… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CUSTOMERS | CUSTOMERS | 85% | In conducting our business, we process, transmit and store sensitive personal and medical data about our customers |
| ACET | Adicet Bio, Inc. | 72% | l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| ACET | Adicet Bio, Inc. | 72% | Reciprocal relationship from ACET graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorpo… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO g… |
| ALLO | Allogene Therapeutics, Inc. | 72% | l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| FATE | Fate Therapeutics, Inc. | 72% | l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE g… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from GILD g… |
| GILD | Gilead Sciences, Inc. | 72% | l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| IMTX | Immatics N.V. | 72% | Reciprocal relationship from IMTX graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IMTX g… |
| IMTX | Immatics N.V. | 72% | l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| IPSC | Century Therapeutics, Inc. | 72% | l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorpo… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the ri… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | ct in currencies other than our respective functional currencies (“foreign currencies”). Currency risk arises when transactions are denominated in foreign currencies other than functional currency. I… |
| COMPANY-THE-GROUP | COMPANY-THE-GROUP | 62% | expense and as a corresponding adjustment to equity over the remaining vesting period, unless the revision to original estimates is due to market conditions. No adjustment is made if the revision or … |
| LONGEVITYBANK-PTE-LTD | LONGEVITYBANK-PTE-LTD | 62% | on of CellSafe International Sdn. Bhd. (In-Liquidation) through our subsidiary LongevityBank Pte. Ltd. (previously known as iPSCBank Pte Ltd) may lead to unforeseen financial and operational difficul… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| GDTC-DEBT | Debt stack $378,064 | 90% | Market cache reports total debt of $378,064. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| GDTC-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 1,065; ownership 0.01%; value $1,278; as of 2025-12-31. |
| GDTC-OWNER-WEALTHSPIRE-ADVISORS-LLC | Wealthspire Advisors, LLC | 95% | 13F/ownership overlay lists Wealthspire Advisors, LLC; shares held 4,835; ownership 0.04%; value $5,802; as of 2025-09-30. |
| GDTC-OWNER-XTX-TOPCO-LTD | XTX Topco Ltd | 90% | 13F overlay lists XTX Topco Ltd as top holder; 3 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| GILD | Gilead Sciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ACET | Adicet Bio, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| CELU | Celularity Inc. | 100.00 | 2 | |
| CAH | Cardinal Health, Inc. | 100.00 | 2 | |
| CRSP | CRISPR Therapeutics AG | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CRIS | Curis, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 |